Related Experiment Videos
Postmenopausal estrogen replacement therapy and risk of AD: a population-based study
S C Waring1, W A Rocca, R C Petersen
1Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
Neurology
|April 2, 1999
Summary
Estrogen replacement therapy may reduce Alzheimer's disease (AD) risk in postmenopausal women. This study found lower estrogen use in women with AD compared to controls, suggesting a protective effect.
Area of Science:
- Neuroscience
- Gerontology
- Endocrinology
Background:
- Limited and conflicting data exist on estrogen therapy's effect on Alzheimer's disease (AD) risk.
- Postmenopausal hormone therapy is a widely discussed topic with potential health implications.
Purpose of the Study:
- To investigate the association between estrogen replacement therapy (ERT) and Alzheimer's disease (AD) in postmenopausal women.
- To clarify the conflicting results from previous studies on ERT and AD risk.
Main Methods:
- A population-based case-control study design was employed.
- 222 postmenopausal women with AD (cases) were matched with 222 women without dementia (controls) by age and enrollment duration.
- Estrogen exposure was defined as use for ≥6 months after menopause and before AD onset, with conditional logistic regression used for analysis.
Main Results:
- No significant difference in age at menarche or menopause was observed between cases and controls.
- Estrogen use was less frequent in AD patients (5%) than in controls (10%), yielding an odds ratio of 0.42 (95% CI, 0.18–0.96; P=0.04).
- A significant inverse association between ERT duration and AD risk was found, even after adjusting for education and age at menopause.
Conclusions:
- Population-based findings suggest ERT is linked to a reduced risk of AD in postmenopausal women.
- Estrogen therapy may play a protective role against Alzheimer's disease development.